You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 12, 2025

Drug Price Trends for NDC 00078-0327


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 00078-0327

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug NameVendorNDCCountPrice ($)Price/Unit ($)DatesPrice Type
COMTAN 200MG TABLETS Novartis Pharmaceuticals Corporation 00078-0327-05 100 758.74 7.58740 2020-09-01 - 2025-08-31 FSS
COMTAN 200MG TABLETS Novartis Pharmaceuticals Corporation 00078-0327-05 100 758.74 7.58740 2021-01-01 - 2025-08-31 FSS
COMTAN 200MG TABLETS Novartis Pharmaceuticals Corporation 00078-0327-05 100 573.77 5.73770 2020-09-01 - 2025-08-31 Big4
COMTAN 200MG TABLETS Novartis Pharmaceuticals Corporation 00078-0327-05 100 573.34 5.73340 2021-01-01 - 2025-08-31 Big4
>Drug Name>Vendor>NDC>Count>Price ($)>Price/Unit ($)>Dates>Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies
Showing 1 to 4 of 4 entries

00078-0327 Market Analysis and Financial Projection

Market Analysis and Price Projections for Drug NDC: 00078-0327

Understanding the NDC Code

The National Drug Code (NDC) is a unique 11-digit code assigned to each drug product by the FDA. It includes the labeler code, product code, and package code. For the NDC 00078-0327, this code identifies a specific drug product, including its name, strength, and dosage form[2].

Drug Identification

To analyze the market and price projections for the drug with NDC 00078-0327, it is crucial to identify the drug. However, the provided sources do not specify the drug name associated with this NDC. Typically, one would refer to the FDA NDC Directory or other pharmaceutical databases to identify the drug.

Market Analysis

Pharmaceutical Industry Outlook

The pharmaceutical industry is expected to experience a stable credit outlook in 2024, driven by revenue growth and balanced market dynamics. In the generic drug sector, mid-single-digit percent annual price erosion is anticipated, along with modest revenue growth. This trend could impact the pricing of generic versions of the drug, if applicable[3].

Specific Market Segments

If the drug falls under a specific therapeutic category, such as oncology (e.g., Non-Small Cell Lung Cancer (NSCLC)), the market analysis would be more nuanced. For instance, the NSCLC market is projected to grow significantly due to the increasing use of immune checkpoint inhibitors and targeted therapies. However, this growth is also influenced by patent expirations and the rise of biosimilars and generics[4].

Price Projections

National Average Drug Acquisition Cost (NADAC)

The NADAC is a critical metric for understanding the average cost at which pharmacies acquire drugs. For any given NDC, the NADAC per unit can be found in the NADAC data files. This cost is influenced by various factors, including recent pharmacy surveys, pricing adjustments, and the classification of the drug as brand or generic[2].

Impact of Generic and Biosimilar Competition

If the drug with NDC 00078-0327 has generic or biosimilar versions, these would significantly impact its price. Generic drugs typically lead to price erosion, as seen in the NSCLC market where generic versions of drugs like Tarceva and Alimta are expected to reduce the sales of their branded counterparts[4].

Regulatory and Compliance Factors

Regulatory actions, such as FDA determinations and compliance issues, can also affect the pricing and availability of a drug. For example, if a drug is determined to be a "new drug" without proper FDA approval, it may be removed from the Medicaid Drug Rebate program, affecting its market presence and pricing[5].

Example: Hypothetical Analysis

If the Drug is a Branded Oncology Medication

  • Market Growth: If the drug is part of the NSCLC market, it could benefit from the overall growth in this segment, driven by the adoption of premium-priced immunotherapies and targeted therapies.
  • Price Erosion: However, as generics and biosimilars enter the market, the branded drug could face significant price erosion. For instance, if a biosimilar version is introduced at a 30% discount, this could substantially reduce the sales of the branded version.

If the Drug is a Generic Medication

  • Price Stability: Generic drugs often experience stable pricing due to competition, but they may still face mid-single-digit percent annual price erosion.
  • Revenue Growth: Despite price erosion, the generic drug sector is expected to see modest revenue growth, driven by increased volume and market share.

Key Takeaways

  • Market Dynamics: The pharmaceutical market is influenced by regulatory actions, generic and biosimilar competition, and overall industry trends.
  • Price Projections: Prices are affected by NADAC, generic competition, and regulatory compliance.
  • Specific Drug Analysis: Identifying the drug associated with NDC 00078-0327 is crucial for a detailed market and price analysis.

FAQs

Q: What is the National Drug Code (NDC)?

  • The NDC is an 11-digit code that identifies the drug name, strength, and dosage form of a drug product, maintained by the FDA[2].

Q: How does the NADAC affect drug pricing?

  • The NADAC reflects the average cost at which pharmacies acquire drugs and is influenced by pharmacy surveys, pricing adjustments, and drug classification[2].

Q: What impact do generics and biosimilars have on drug prices?

  • Generics and biosimilars typically lead to significant price erosion for branded drugs, as they offer cheaper alternatives[4].

Q: How do regulatory actions affect drug pricing and availability?

  • Regulatory actions, such as FDA determinations, can remove drugs from rebate programs or affect their market presence, impacting pricing and availability[5].

Q: What are the key factors influencing the pharmaceutical industry's credit outlook in 2024?

  • The credit outlook is influenced by revenue growth, balanced market dynamics, and the impact of generic and biosimilar competition[3].

Sources

  1. Drug Name and National Drug Code (NDC) Reference Data Instructions - CMS
  2. National Average Drug Acquisition Cost (NADAC) Data Field Definitions - Medicaid
  3. Pharmaceutical Industry 2024 Credit Outlook Is Stable As Revenue Growth Mitigates Pressures - S&P Global
  4. NSCLC MARKET - Global Drug Forecast & Market Analysis to 2025 - Drug Development & Delivery
  5. For State Medicaid Directors: Release No. 150 - Medicaid

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.